BUENA, N.J., June 2, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its second abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to fifteen, with thirteen now pending at the FDA.
Jason Grenfell-Gardner, President and CEO of the Company, commented, "We now have thirteen ANDAs pending approval and on file with the FDA. Our 2014 goal of at least ten ANDA submissions remains on track. We have set expectations very high, and we believe June will be the most productive month for submissions in the company's history. Our team is focused and prepared to continue to execute. We believe our current pipeline of submissions pending approval by the FDA has a combined addressable market of over $370 million based on recent data from IMS Health."
About IGI Laboratories, Inc.
IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.
For further information:
Jenniffer Collins, IGI Laboratories, Inc.
(856) 697-4379, www.igilabs.com